Department of Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.
Anticancer Drugs. 2013 Apr;24(4):337-43. doi: 10.1097/CAD.0b013e32835ec39a.
Globally, hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection leads to liver fibrosis and cirrhosis, which in turn causes resultant hepatocellular carcinoma (HCC). Frequently, HCC recurs very soon even after a potentially curative treatment such as surgical interference or locoregional ablative therapies. Chronic HBV/HCV infection is often responsible for this recurrence, through secondary carcinogenesis. Antiviral therapy after a curative treatment of HCC plays an important role in preventing or delaying recurrence and improves survival in patients with HBV/HCV infection-related HCC. This article reviews the worldwide epidemiology of HBV/HCV infection, the association of viral infection with HCC, the mechanism of hepatitis virus-related hepatocarcinogenesis, and the paramount importance of antiviral therapy in the management of HCC.
在全球范围内，乙型肝炎病毒（HBV）和/或丙型肝炎病毒（HCV）感染可导致肝纤维化和肝硬化，进而导致肝细胞癌（HCC）。即使在根治性治疗（如手术干预或局部消融治疗）后， HCC 也经常很快复发。慢性 HBV/HCV 感染通常通过继发致癌作用导致这种复发。HCC 根治性治疗后进行抗病毒治疗对于预防或延迟复发以及改善 HBV/HCV 感染相关 HCC 患者的生存具有重要作用。本文综述了 HBV/HCV 感染的全球流行病学、病毒感染与 HCC 的关系、肝炎病毒相关肝癌发生的机制，以及抗病毒治疗在 HCC 管理中的重要性。
